A Phase 4 interventional study of Insulin LISPRO intravenous loading in Diabetes Mellitus and Ventricular Dysfunction, sponsored by Rambam Health Care Campus. Completed at 1 site in Israel. Open to male participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-15.
Sponsored by Rambam Health Care Campus · Phase 4, Interventional, and Treatment
Our investigation studies the role of acute insulin administration on the diabetic heart, its corresponding effective blood-insulin level and the time-course applicability of insulin in a routine clinical setting.
A case series of six male (48.1 ± 4.9 y/o) patients with controlled diabetes (HbA1c of 6.6 ± 0.3%, disease duration of 14.4 ± 6.7 yr). Each subject was evaluated for glucose homeostatic, hemodynamic and echocardiographic systolic and diastolic parameters at baseline and following two successive insulin-load steps of a euglycemic hyperinsulinemic clamp study, each 2 h in duration. Results are presented as a mean ± SEM and analysed using the student's t-test.
Patients:
Six male diabetic (five type 2 and one type 1) patients, 30-65 year old, with an established diagnosis of diabetes mellitus for ≥2 years, who were free of significant valvular heart disease, atrial arrhythmia or cardiac pacing comprised the study population. Patients' characteristics are summarized in table 1.
Each patient served as his or her own control. The study protocol was approved by the ethics committee at Rambam Medical Center, Haifa, Israel. Prior to the study, patients gave written informed consent after receiving a detailed explanation as to the purpose of the study, the technique, its side effects and the study protocol.
Patients were studied within a clinical research facility at the Rambam Medical Center, Haifa, Israel. Baseline evaluation was conducted at 8:00 am after 12 h of fasting, followed by two hyperinsulinemic euglycemic clamp (EHC) steps (2 h each step); The following vital signs were monitored during the study protocol: manual heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP) and baseline 12-lead electrocardiogram (ECG) recording. Glucose consumption rates against changing insulin levels were measured by the EHC technique. Cardiac function parameters were measured in the last 10 min of each step by tissue Doppler echocardiography. Results are presented as a mean ± SEM.
Clamp technique:
Each patient underwent an EHC study according to the protocol described previously, and implemented in our institute. Baseline measurements of blood insulin and glucose levels were collected. Thereafter, two insulin loads were initiated. The blood glucose level was kept near euglycemia (90 ± 5 mg/dl) throughout 2 h period of each insulin load step. Intravenous (iv) insulin loads were administered by 1- and 10-mU/kg·min at steps 1 and 2 of insulin loading (Lispro Insulin, Eli Lilly, France), respectively. Dexstrose in water 50% (DW50) was infused at variable infusion rates, titrated to maintain euglycemia. Concomitant saline 0.45% was used to dilute the DW50 in order to prevent hypertonicity-induced irritation of the cannuled vein. During the baseline period, saline 0.45% infusion rates were 0.75 ml/min to keep the iv cannule open. Every patient was given a chance to urinate before step 2.
Glucose and insulin homeostatic parameters of the study group were compared to those of healthy controls we studied earlier.
Cardiac function assessment:
Transthoracic echocardiography was performed by a qualified echocardiographer using a General Electric Vivid 3 machine (Tirat HaCarmel, Israel). Parameters were assessed as the mean of three consecutive heart beats.
Systolic echocardiographic parameters:
LV fractional shortening (LVFS) derived from end diastolic and end systolic LV dimensions; LV ejection fraction (LVEF) derived from end diastolic and end systolic LV volumes.
Diastolic echocardiographic parameters:
Results are presented as mean ± SEM and analyzed using the student's t-test. Statistical significance considered when p value less than 0.05.
262 studies on the registry are indexed under Ventricular Dysfunction; 40 are open to participants now.
This study's enrollment of 6 is below the median of 63 across 144 interventional studies indexed under Ventricular Dysfunction.
Browse Ventricular Dysfunction studies →Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons. Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading
Drug: Insulin LISPRO intravenous loading
intravenous infusion of insulin Lispro.
Also known as: Humalog Insulin
Left ventricle ejection fraction (%)
Time frame: 1 year
Time needed to exert insulin effect on myocardial function (hour)
Describe the shortest time required for insulin to change myocardial function.
Time frame: 1 year
Blood insulin levels (μU/ml: micro international unit per milliliter)
Time frame: 1 year
Left ventricle fractioning shortening (%)
Time frame: 1 year
E wave (centimeter per second)
Time frame: 1 year
A wave (centimeter per second)
Time frame: 1 year
E deceleration time (seconds)
Time frame: 1 year
E' (centimeters)
Time frame: 1 year
A' (centimeters)
Time frame: 1 year
Plan to share: Undecided — First we need to learn how to share data
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rambam Health Care Campus